Spark Therapeutics Announces Closing of Public Offering
August 09 2017 - 4:05PM
Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today
the closing of the previously announced underwritten public
offering of its common stock pursuant to an automatically effective
shelf registration statement that was previously filed with the
Securities and Exchange Commission, including the exercise in full
by the underwriters of their option to purchase an additional
690,789 shares from Spark at the public offering price of $76.00
per share, less the underwriting discount. The exercise of the
option brought the total number of shares sold in the offering to
5,296,053, and increased the aggregate net proceeds to Spark to
approximately $380.4 million, after deducting underwriting
discounts and before offering expenses.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and
Cowen and Company, LLC acted as book-running managers for the
offering. Copies of the final prospectus supplement and
accompanying prospectus relating to this offering may be obtained
from: J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by
telephone at (866) 803-9204; Goldman Sachs & Co. LLC, Attn:
Prospectus Department, 200 West Street, New York, NY 10282,
telephone: (866) 471-2526, facsimile: (212) 902-9316, e-mail:
prospectus-ny@ny.email.gs.com; or Cowen and Company, LLC c/o
Broadridge Financial Services, 1155 Long Island Avenue, Edgewood,
NY, 11717, Attn: Prospectus Department, by calling (631) 274-2806
or by faxing (631) 254-7140.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification of these securities under the securities laws of any
such state or jurisdiction.
About Spark Therapeutics
Spark Therapeutics, a fully integrated company, strives to
challenge the inevitability of genetic disease by discovering,
developing, and delivering gene therapies that address inherited
retinal diseases (IRDs), neurodegenerative diseases, as well as
diseases that can be addressed by targeting the liver, such as
hemophilia. Spark has ongoing clinical trials investigating gene
therapies in hemophilia A and B. SPK-8011 is in an ongoing,
dose-escalation Phase 1/2 clinical trial as a potential one-time
therapy for hemophilia A. Spark retains full global
commercialization rights to the SPK-FVIII program. SPK-9001, which
has received both breakthrough therapy and orphan product
designations by the U.S. Food and Drug Administration (FDA), and
access to the PRIority MEdicines (PRIME) Program by the European
Medicines Agency (EMA), is in a Phase 1/2 clinical trial for
hemophilia B and is being developed in collaboration with Pfizer,
Inc. Our most advanced investigational candidate, with proposed
trade name LUXTURNA™ (voretigene neparvovec), is currently under
Priority Review with FDA for the treatment of biallelic
RPE65-mediated IRD and has been designated as a drug for a rare
pediatric disease. The marketing authorization application for
LUXTURNA has been submitted to EMA for the treatment of vision loss
due to Leber congenital amaurosis or retinitis pigmentosa caused by
confirmed biallelic RPE65 mutations. LUXTURNA has received
breakthrough therapy and orphan product designations from FDA and
orphan product designations from EMA. The pipeline also includes
SPK-7001 in an ongoing Phase 1/2 clinical trial for
choroideremia.
Contacts
Spark Therapeutics, Inc.
Stephen W. Webster
Chief Financial Officer
(855) SPARKTX (1-855-772-7589)
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Apr 2023 to Apr 2024